Welcome to our dedicated page for MANHATTAN SCIENTIFICS news (Ticker: MHTX), a resource for investors and traders seeking the latest updates and insights on MANHATTAN SCIENTIFICS stock.
Manhattan Scientifics Inc. (MHTX) is a pioneering company focused on innovative technology in the nanomedicine space. With a strong emphasis on disruptive solutions, Manhattan Scientifics aims to establish sustainable businesses by leveraging cutting-edge advancements in the field. The company is dedicated to pushing the boundaries of science and technology to create impactful products that have the potential to revolutionize the healthcare industry.
Manhattan Scientifics Inc. (OTCQB: MHTX) announced positive early results from the human study of Imagion Biosystems' cancer diagnostic technology. Following the announcement, shares of Imagion Biosystems (IBX.AX) surged by 46%, reaching 71 million in trading volume. Manhattan Scientifics owns over 50 million shares of Imagion, indicating a significant investment in the company’s future. The press release highlights the innovative diagnostic technology aimed at early cancer detection, emphasizing its non-radioactive and super-sensitive nature.
Manhattan Scientifics Inc. (OTC: QB) holds over 50 million shares of Imagion Biosystems (IBX.AX), focused on developing advanced non-radioactive cancer imaging technology. A televised interview with Imagion's CEO, Bob Proulx, is highlighted, discussing their innovative diagnostic solutions aimed at early cancer detection. The press release emphasizes the partnership and technology transfer efforts with Los Alamos and Sandia National Laboratories in New Mexico. The company warns that investments are high risk, with future results uncertain, stressing forward-looking statements are not guarantees of performance.
Manhattan Scientifics Inc. (OTCQB: MHTX) has invested $30 million and committed to a 10-year effort to commercialize a non-invasive cancer diagnostic in partnership with MD Anderson Cancer Center. The company is currently awaiting regulatory approval to commence human trials. The CEO expressed intentions to enhance shareholder value, despite the company's market cap fluctuations, which have seen a peak near $1 billion and a low of $17 million.
Manhattan Scientifics Inc. (OTCQB: MHTX) announced year-end updates on its Nano-Medicine Cancer and Nano-Medical Metal Alloy initiatives. The company owns over 50 million shares of Imagion Biosystems Ltd. (ASX: IBX), which has made significant progress, including establishing clinical trials and increasing cash reserves to $10.13 million. MHTX also anticipates royalties from its licensed nano-metal technology for medical prosthetics, expecting to start earning in 2021. Management emphasizes low overhead and a strong commitment to the company's growth.
FAQ
What is the current stock price of MANHATTAN SCIENTIFICS (MHTX)?
What is the market cap of MANHATTAN SCIENTIFICS (MHTX)?
What is Manhattan Scientifics Inc. known for?
What is the core business of Manhattan Scientifics Inc.?
What sets Manhattan Scientifics Inc. apart from other companies?
How does Manhattan Scientifics Inc. aim to revolutionize the healthcare industry?
What is the mission of Manhattan Scientifics Inc.?
What recent achievements has Manhattan Scientifics Inc. accomplished?
How does Manhattan Scientifics Inc. approach partnerships and collaborations?
What products does Manhattan Scientifics Inc. offer?
What is the financial condition of Manhattan Scientifics Inc.?
What are some of the current projects of Manhattan Scientifics Inc.?
